CD19 and non-Hodgkin lymphoma: ,2,3,4,5,6 Since the first report in 2010, the US Food and Drug Administration has approved four anti-CD19 products in non-Hodgkin lymphoma (NHL), all of which belong to the second-generation (2nd Gen) CD19 CAR T cell product family.7